Minimal residual disease in autologous hematopoietic harvests from breast cancer patients.
The increasing use of high-dose chemotherapy with autologous hematopoietic transplantation for the treatment of solid malignancies has raised concern about the role of tumor cells contaminating the grafts. Minimal residual disease (MRD) in autologous grafts has became a dynamic and intensively studied field in oncology. This review discusses the current status of MRD in breast cancer autografts and presents existing data on detection methodology, clinical relevance, biologic characteristics and purging techniques.
Spyridonidis
A
A
Department of Hematology/Oncology, University Medical Center, Freiburg, Germany.
Bernhardt
W
W
Fetscher
S
S
Behringer
D
D
Mertelsmann
R
R
Henschler
R
R
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000473:pathology / Q000628:therapy*; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D018365:Neoplasm, Residual; D016896:Treatment Outcome
D000970:Antineoplastic Agents